Acumen director granted RSUs and stock options
Acumen Pharmaceuticals director Nathan B. Fountain received new equity awards as part of his compensation.
Rhea-AI Filing Summary
Acumen Pharmaceuticals director Nathan B. Fountain received new equity awards as part of his compensation. He was granted 35,500 shares of common stock in the form of restricted stock units, bringing his direct common stock holdings to 54,550 shares after the award. He also received stock options for 53,250 shares with an exercise price of $2.29 per share. Both the RSUs and options vest in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting, provided he continues serving the company through that date.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 88,750 shares
Grant/Award
2 txns
Insider
Fountain Nathan B
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 53,250 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 35,500 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 53,250 contracts (Direct);
Common Stock — 54,550 shares (Direct)
Footnotes (2)
- F1. Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
- F2. The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.
Key Figures
RSU award: 35,500 shares
Common stock held: 54,550 shares
Stock options granted: 53,250 options
+2 more
5 metrics
RSU award
35,500 shares
Restricted stock units granted to director
Common stock held
54,550 shares
Direct holdings after RSU grant
Stock options granted
53,250 options
Right to buy common stock
Option exercise price
$2.29 per share
Strike price for newly granted options
Option expiration
June 3, 2036
Expiration date of granted options
Key Terms
restricted stock unit ("RSU"), continuous service, Stock Option (right to buy), annual stockholder meeting, +1 more
5 terms
restricted stock unit ("RSU") financial
"Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share"
continuous service financial
"subject to the Reporting Person's continuous service through such vesting date"
Stock Option (right to buy) financial
"Stock Option (right to buy)"
annual stockholder meeting financial
"on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting"
An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.
exercise price financial
"conversion_or_exercise_price": "2.2900""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Acumen Pharmaceuticals (ABOS) disclose for Nathan B. Fountain?
Acumen Pharmaceuticals disclosed that director Nathan B. Fountain received equity awards, including restricted stock units and stock options. These awards are compensation-related grants rather than open-market purchases or sales of Acumen Pharmaceuticals common stock.
What stock options were granted to Nathan B. Fountain at Acumen Pharmaceuticals (ABOS)?
Nathan B. Fountain was granted options covering 53,250 shares of Acumen Pharmaceuticals common stock with an exercise price of $2.29 per share. These options give him the right to buy shares at that fixed price if and when they vest.
When do Nathan B. Fountain’s RSUs and options at Acumen Pharmaceuticals (ABOS) vest?
Both the restricted stock units and the stock options vest in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting. Vesting requires his continuous service with Acumen Pharmaceuticals through that vesting date.
Are Nathan B. Fountain’s Acumen Pharmaceuticals (ABOS) awards tied to continued service?
Yes. The RSU and stock option awards vest only if Nathan B. Fountain maintains continuous service with Acumen Pharmaceuticals through vesting. If he does not remain in service until the vesting date, the awards may not fully vest as described.
Do Nathan B. Fountain’s Acumen Pharmaceuticals (ABOS) transactions involve open-market buying or selling?
No. The filing shows compensation-related grants of restricted stock units and stock options, coded as awards. There are no open-market purchases or sales; the shares and options were granted at no cash cost per share in the reported transactions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
